Harrow Inc (HROW)

$10.85

-0.97

(-8.21%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Harrow Inc

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 20.32M → 36.35M (in $), with an average increase of 13.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -4.22M → -9.14M (in $), with an average decrease of 56.1% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 33.0% return, outperforming this stock by 83.0%

Performance

  • $10.83
    $11.87
    $10.85
    downward going graph

    0.18%

    Downside

    Day's Volatility :8.75%

    Upside

    8.59%

    downward going graph
  • $7.60
    $28.25
    $10.85
    downward going graph

    29.95%

    Downside

    52 Weeks Volatility :73.1%

    Upside

    61.59%

    downward going graph

Returns

Period Harrow IncSector (Health Care)Index (Russel 2000)
3 Months
20.24%
-0.7%
0.0%
6 Months
-24.08%
6.6%
0.0%
1 Year
-50.02%
3.7%
-1.5%
3 Years
40.21%
14.0%
-21.8%

Highlights

Market Capitalization
435.0M
Book Value
$2.01
Earnings Per Share (EPS)
-0.75
Wall Street Target Price
25.65
Profit Margin
-18.75%
Operating Margin TTM
-12.36%
Return On Assets TTM
0.22%
Return On Equity TTM
-50.0%
Revenue TTM
130.2M
Revenue Per Share TTM
3.99
Quarterly Revenue Growth YOY
78.8%
Gross Profit TTM
63.2M
EBITDA
11.9M
Diluted Eps TTM
-0.75
Quarterly Earnings Growth YOY
-0.64
EPS Estimate Current Year
-0.32
EPS Estimate Next Year
0.59
EPS Estimate Current Quarter
-0.04
EPS Estimate Next Quarter
-0.01

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Harrow Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 136.41%

Current $10.85
Target $25.65

Company Financials

FY18Y/Y Change
Revenue
41.4M
↑ 54.52%
Net Income
14.6M
↓ 222.03%
Net Profit Margin
35.35%
↑ 80.11%
FY19Y/Y Change
Revenue
51.2M
↑ 23.67%
Net Income
-2.6M
↓ 117.72%
Net Profit Margin
-5.07%
↓ 40.42%
FY20Y/Y Change
Revenue
48.9M
↓ 4.48%
Net Income
-3.4M
↑ 31.91%
Net Profit Margin
-7.0%
↓ 1.93%
FY21Y/Y Change
Revenue
72.5M
↑ 48.3%
Net Income
-18.0M
↑ 426.67%
Net Profit Margin
-24.85%
↓ 17.85%
FY22Y/Y Change
Revenue
88.6M
↑ 22.24%
Net Income
-14.1M
↓ 21.77%
Net Profit Margin
-15.9%
↑ 8.95%
FY23Y/Y Change
Revenue
130.2M
↑ 46.95%
Net Income
-24.4M
↑ 73.3%
Net Profit Margin
-18.75%
↓ 2.85%
Q3 FY22Q/Q Change
Revenue
22.8M
↓ 2.14%
Net Income
-6.5M
↑ 3.61%
Net Profit Margin
-28.32%
↓ 1.57%
Q4 FY22Q/Q Change
Revenue
20.3M
↓ 10.93%
Net Income
1.1M
↓ 116.32%
Net Profit Margin
5.19%
↑ 33.51%
Q1 FY23Q/Q Change
Revenue
26.1M
↑ 28.4%
Net Income
-6.6M
↓ 729.67%
Net Profit Margin
-25.45%
↓ 30.64%
Q2 FY23Q/Q Change
Revenue
33.5M
↑ 28.22%
Net Income
-4.2M
↓ 36.34%
Net Profit Margin
-12.64%
↑ 12.81%
Q3 FY23Q/Q Change
Revenue
34.3M
↑ 2.38%
Net Income
-4.4M
↑ 3.83%
Net Profit Margin
-12.81%
↓ 0.17%
Q4 FY23Q/Q Change
Revenue
36.4M
↑ 6.1%
Net Income
-9.1M
↑ 108.34%
Net Profit Margin
-25.16%
↓ 12.35%
FY18Y/Y Change
Total Assets
49.5M
↑ 106.76%
Total Liabilities
24.7M
↑ 15.95%
FY19Y/Y Change
Total Assets
59.1M
↑ 19.48%
Total Liabilities
31.7M
↑ 28.21%
FY20Y/Y Change
Total Assets
57.5M
↓ 2.73%
Total Liabilities
30.6M
↓ 3.22%
FY21Y/Y Change
Total Assets
98.3M
↑ 71.08%
Total Liabilities
87.4M
↑ 185.19%
FY22Y/Y Change
Total Assets
157.0M
↑ 59.69%
Total Liabilities
130.1M
↑ 48.9%
FY23Y/Y Change
Total Assets
311.8M
↑ 98.54%
Total Liabilities
241.8M
↑ 85.77%
Q3 FY22Q/Q Change
Total Assets
99.0M
↑ 0.95%
Total Liabilities
98.1M
↑ 5.89%
Q4 FY22Q/Q Change
Total Assets
157.0M
↑ 58.62%
Total Liabilities
130.1M
↑ 32.62%
Q1 FY23Q/Q Change
Total Assets
217.5M
↑ 38.51%
Total Liabilities
196.0M
↑ 50.59%
Q2 FY23Q/Q Change
Total Assets
224.0M
↑ 2.98%
Total Liabilities
201.9M
↑ 3.04%
Q3 FY23Q/Q Change
Total Assets
286.1M
↑ 27.71%
Total Liabilities
210.7M
↑ 4.32%
Q4 FY23Q/Q Change
Total Assets
311.8M
↑ 8.98%
Total Liabilities
241.8M
↑ 14.76%
FY18Y/Y Change
Operating Cash Flow
687.0K
↓ 107.8%
Investing Cash Flow
-2.2M
↑ 128.82%
Financing Cash Flow
4.1M
↓ 16.21%
FY19Y/Y Change
Operating Cash Flow
950.0K
↑ 38.28%
Investing Cash Flow
-1.8M
↓ 16.64%
Financing Cash Flow
-1.0M
↓ 124.35%
FY20Y/Y Change
Operating Cash Flow
-1.1M
↓ 215.79%
Investing Cash Flow
-981.0K
↓ 46.48%
Financing Cash Flow
1.4M
↓ 242.45%
FY21Y/Y Change
Operating Cash Flow
5.1M
↓ 562.0%
Investing Cash Flow
-18.7M
↑ 1804.79%
Financing Cash Flow
51.5M
↑ 3491.77%
FY22Y/Y Change
Operating Cash Flow
1.7M
↓ 66.45%
Investing Cash Flow
-1.7M
↓ 90.67%
Financing Cash Flow
54.1M
↑ 5.19%
Q3 FY22Q/Q Change
Operating Cash Flow
-410.0K
↓ 108.44%
Investing Cash Flow
-1.1M
↑ 312.74%
Financing Cash Flow
55.0M
↓ 49674.77%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.7M
↑ 805.37%
Investing Cash Flow
-5.0K
↓ 99.53%
Financing Cash Flow
55.0M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-8.2M
↑ 121.28%
Investing Cash Flow
-131.0M
↑ 2619300.0%
Financing Cash Flow
62.2M
↑ 12.96%
Q2 FY23Q/Q Change
Operating Cash Flow
4.6M
↓ 155.59%
Investing Cash Flow
-1.2M
↓ 99.05%
Financing Cash Flow
189.0K
↓ 99.7%

Technicals Summary

Sell

Neutral

Buy

Harrow Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Harrow Inc
Harrow Inc
12.68%
-24.08%
-50.02%
40.21%
40.21%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-4.45%
18.72%
28.45%
40.46%
69.87%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.12%
-1.82%
-7.31%
9.45%
9.45%
Zoetis Inc.
Zoetis Inc.
-10.98%
-10.38%
-12.9%
-9.61%
53.43%
Viatris Inc.
Viatris Inc.
-5.61%
18.46%
12.35%
-16.23%
-32.07%
Catalent, Inc.
Catalent, Inc.
0.0%
24.33%
32.98%
-48.49%
27.27%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Harrow Inc
Harrow Inc
NA
NA
NA
-0.32
-0.5
0.0
NA
2.01
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
53.84
53.84
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.93
28.93
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.48
29.48
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
222.4
222.4
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Harrow Inc
Harrow Inc
Buy
$435.0M
40.21%
NA
-18.75%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.4B
69.87%
53.84
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.0B
9.45%
28.93
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.5B
53.43%
29.48
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-32.07%
222.4
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
27.27%
211.02
-31.77%

Institutional Holdings

  • Opaleye Management Inc

    10.80%

  • Private Capital Management, LLC

    7.90%

  • BlackRock Inc

    6.28%

  • BRAIDWELL LP

    5.11%

  • Vanguard Group Inc

    5.11%

  • Morgan Stanley - Brokerage Accounts

    3.86%

Corporate Announcements

  • Harrow Inc Earnings

    Harrow Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas

Organization
Harrow Inc
Employees
315
CEO
Mr. Mark L. Baum J.D.
Industry
Health Technology

Discover More

FAQs